Discover

PODD
Insulet Corporation
148.99
1 x 135.93
1 x 160.38
bid
ask
+
5.09
3.54%
03:40 PM
timesize
Ytd -47.58%
1y -52.08%
144.82
day range
149.48
138.97
52 week range
352.82
Open 144.83 Prev Close 143.90 Low 144.82 High 149.48 Mkt Cap 10.32B
Vol 929.72K Avg Vol 1.41M EPS 4.28 P/E 34.80 Forward P/E 17.20
Beta 1.13 Short Ratio 2.20 Inst. Own 105.53% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 08-06 50-d Avg 162.82 200-d Avg 254.38 1yr Est 242.44
Earning
Date For Estimate Reported Surprise surprise %
2026-05-06 2026-03 1.14 1.42 0.28 24.56%
2026-02-18 2025-12 1.48 1.55 0.07 4.73%
2025-11-06 2025-09 1.13 1.24 0.11 9.73%
2025-08-07 2025-06 0.93 1.17 0.24 25.81%
2025-05-08 2025-03 0.81 1.02 0.21 25.93%
2025-02-20 2024-12 1.05 1.15 0.1 9.52%
Upgrade / Downgrade
Date Firm Action From To
2026-06-23 Deutsche Bank Upgrade Buy
2026-06-12 Truist Securities Upgrade Buy Buy
2026-05-28 Citigroup Upgrade Neutral Neutral
2026-05-27 RBC Capital Upgrade Outperform Outperform
2026-05-27 BTIG Upgrade Buy Buy
2026-05-18 B of A Securities Upgrade Buy Buy
Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2026-02-23 BENJAMIN ERIC Chief Operating Officer 24.51K Stock Award(Grant)
2025-02-24 CHADWICK ANA MARIA Chief Financial Officer 16.03K Stock Award(Grant)
2025-02-24 FIELD MARK N Chief Technology Officer 13.92K Stock Award(Grant)
2025-02-24 HOLLINGSHEAD JAMES R Chief Executive Officer 68.07K Stock Award(Grant)
2026-05-19 HOPFIELD JESSICA Director 29.36K Stock Award(Grant)
2026-02-23 KAPPLES JOHN W. General Counsel 28.12K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 Blackrock Inc. 6.38M 917.50M 9.21%
2026-03-30 Vanguard Capital Management LLC 4.58M 658.96M 6.61%
2026-03-30 FMR, LLC 3.97M 571.96M 5.74%
2026-03-30 Vanguard Portfolio Management LLC 3.45M 496.45M 4.98%
2026-03-30 State Street Corporation 3.04M 437.81M 4.39%
2026-03-30 BAILLIE GIFFORD & CO 2.03M 292.04M 2.93%
Fund Ownership
Report Date Organization Position Value Percentage
2026-03-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 2.24M 322.45M 3.24%
2026-03-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 1.79M 257.20M 2.58%
2026-04-29 iShares Trust-iShares Core S&P 500 ETF 910.27K 130.99M 1.31%
2026-03-30 AMCAP FUND 900.00K 129.51M 1.30%
2026-04-29 Fidelity Concord Street Trust-Fidelity 500 Index Fund 901.49K 129.72M 1.30%
2026-04-29 Fidelity Securities Fund-Fidelity OTC Portfolio 889.38K 127.98M 1.28%